Autosomal dominant spinocerebellar ataxias (SCAs) are a heterogeneous group of neurodegenerative disorders. In this study, we performed genetic analysis of a unique form of SCA (SCA36) that is accompanied by motor neuron involvement.
onset of cerebellar ataxia was 52.8 ± 4.3 years, and the disease was transmitted by an autosomal dominant mode of inheritance. All affected individuals started their ataxic symptoms, such as gait and truncal instability, ataxic dysarthria, and uncoordinated limbs, in their late forties to fifties. Magnetic resonance imaging revealed relatively confined and mild cerebellar atrophy (Figure 2A) . Unlike previously known SCAs, all affected individuals with longer disease duration showed obvious signs of motor neuron involvement ( Table 1) . Characteristically, all affected individuals exhibited tongue atrophy with fasciculation to a greater or lesser extent (Figure 2B) . Despite severe tongue atrophy in some cases, their swallowing function was relatively preserved, and they were allowed oral intake even at a later point after onset. In addition to tongue atrophy, skeletal muscle atrophy and fasciculation in the limbs and trunk appeared in advanced cases 4 . Tendon reflexes were generally mild-to-severely hyperreactive in most affected individuals, without severe lower limb spasticity and extensor plantar response.
Electrophysiological studies were performed in an affected individual. Nerve conduction studies revealed normal findings in all the cases examined; however, an electromyogram showed neurogenic changes only in cases with skeletal muscle atrophy, indicating that lower motor neuropathy existed in this particular disease. Progression of motor neuron involvement in this SCA was typically and limited to the tongue and main proximal skeletal muscles in both upper and lower extremities, which is clearly different from typical ALS, which usually involves most skeletal muscles in a few years, leading to fatal results within several years.
We conducted genome-wide linkage analysis for nine affected subjects and eight unaffected subjects in three informative families (Pedigrees 1-3; Figure 1 ). For genotyping, we used an ABI Prism Linkage Mapping Set (Version 2; Applied Biosystems, Foster City, CA, USA) with 382 markers, 10 cM apart, for 22 autosomes.
Fine-mapping markers (approximately 1 cM apart) were designed according to information from the uniSTS reference physical map in the NCBI database. A parametric linkage analysis was carried out using GENEHUNTER 8 , assuming an autosomal dominant model. The disease allele frequency was set at 0.000001 and a phenocopy frequency of 0.000001 was assumed. Population allele frequencies were assigned equal portions for individual alleles. We performed multipoint analyses for autosomes and obtained logarithm of the odds (LOD) scores. We considered LOD scores above 3.0 to be significant 8 . Genome-wide linkage analysis revealed a single locus on chromosome 20p13 with a LOD score of 3.20. Fine mapping increased the LOD score to 4.60 (Figure 3) . Haplotype analysis revealed two recombination events in pedigree 3, delimiting a1.8-Mb region (D20S906-D20S193) (Figure 1) . We further tested whether the five cases shared the haplotype. As shown in Figure 1 , pedigrees 4 and 5 were confirmed to have the same haplotype as pedigrees 1, 2, and 3, indicating that the 1.8 Mb region is very likely to be derived from a common ancestor. The 1.8-Mb region harbors 44 genes (NCBI, Build 37.1). We eliminated two pseudogenes and five genes (LOC441938, LOC100289473, LOC100288797, LOC100289507 and LOC100289538) from the candidates. Evidence view showed that the first, fourth, and fifth genes were not found in the contig in this region, while the second and third of these genes had mismatches over the mouse genes. Sequence similarities among paralogue genes defied direct sequencing of four genes: SIRPD Figure 2C) . All noncoding and coding exons, and the 100 bp up-and down-stream of the splice junctions of these genes were sequenced in two index cases (IV-4 in pedigree1 and III-1 in pedigree 3) and in three additional cases (II-1 in pedigree 2, II-1 in pedigree 4 and II-1 in pedigree 5) using specific primers (Supplemental Table 1 ).
Eight unregistered variants were found among the two index cases. Among these, there was a coding variant (Phe265Leu), g.3324373 C > G of C20orf194, while the other seven included one synonymous variant (Leu565Leu in ZNF343; g.2463912 T>A) and six non-splice-site intronic variants (supplemental Table 2 ). We tested segregation by sequencing exon 11 of C20orf194 in IV-2 and III-5 in the pedigree 1. Neither IV-2 nor III-5 had this variant. We thus eliminated C20orf194 as a candidate. Missense mutations in PDYN and TGM6, which have been recently reported as causes of SCA, mapped to 20p12.3-p13 9; 10 , but none were detected in the five index cases studied here (Supplemental Table 2 ).
Possible expansions of repetitive sequences in these 33 genes were investigated when intragenic repeats were indicated in the database (UCSC Genome 7 Bioinformatics). Expansions of the hexanucleotide repeat GGCCTG (rs68063608) were found in intron 1 of NOP56 (Figure 2D ) in all five index cases, using a repeat-primed PCR method [11] [12] [13] . An outline of the repeat-primed PCR experiment is described in Figure 2D . Briefly, the fluorescent dye-conjugated forward primer corresponded to the region upstream of the repeat of interest. The first reverse primer consisted of four units of the repeat (GGCCTG) and a 5′-tail used as an anchor. The second reverse primer was an "anchor" primer. These primers are described in Supplemental Table 3 . Complete segregation of the expanded hexanucleotide was confirmed in all pedigrees, and the maximum repeat size in nine unaffected members was eight (data not shown).
In addition to the SCA cases in five pedigrees, four unrelated cases (SCA#1-SCA#4) were found to have a (GGCCTG)n allele by screening in the cohort SCA patients ( Table 1) . Neurological examination was reevaluated in these four cases, revealing both ataxia and motor neuron dysfunction with tongue atrophy and fasciculation ( Table 1) . Totally nine unrelated cases were found in the 251 cohort patients with SCA (3.6%). To confirm the repeat expansions, Southern blot analysis was conducted in six affected subjects (Ped2_II-1, Ped3_III-1, Ped3_III-2, Ped5_I-1, Ped5_II-1 and SCA#1). The data showed >10 kb of repeat expansions in the lymphoblastoid cell lines (LCLs) obtained from the SCA patients (Figure 2E) .
Furthermore, the numbers of GGCCTG repeat expansion were estimated by Southern blotting in other 11 cases. The expansion analysis revealed approximately 1500 to 2500 in 17 cases ( Table 1) . There was no negative association between age of onset and the number of GGCCTG repeats (n=17, r=0.42, p=0.09; Supplemental Figure 1 ), and no obvious anticipation in the current pedigrees. 8 To investigate the disease specificity and disease spectrum of the hexanucleotide repeat expansions, we tested the repeat expansions in an Alzheimer's disease [MIM 104300] cohort and an ALS cohort followed up by the Department of Neurology, Okayama University Hospital. We also recruited Japanese controls, who were confirmed to be free from brain lesions by magnetic resonance imaging and magnetic resonance angiography, as described previously 14 . Screening of the 27 Alzheimer's disease cases and 154 ALS cases failed to detect further cases with repeat expansions.
The GGCCTG repeat sizes ranged from three to eight in 300 Japanese controls (5.9 ± 0.8 repeats), suggesting that the >10-kb repeat expansions were mutations.
Expression of Nop56, an essential component of the splicing machinery 15 , was examined by RT-PCR using primers for wild-type mouse Nop56 cDNA (Supplemental Table 3 ). Expression of Nop56 mRNA was detected in various tissues including central nervous system, while a very weak signal was detected in spinal cord ( Figure 4A) .
Immunohistochemistry using an anti-mouse Nop56 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) detected the Nop56 protein in Purkinje cells of the cerebellum as well as motor neurons of the hypoglossal nucleus and the spinal cord anterior horn ( Figure 4B ), suggesting that these cells may be responsible for tongue and muscle atrophy in the trunk and limbs, respectively. Western blotting also confirmed the presence of the Nop56 protein in neural tissues (Figure 4C) , where Nop56 is localized in both the nucleus and cytoplasm.
Alterations of NOP56 RNA expression and protein levels in LCLs from patients were examined by real-time RT-PCR and western blotting. The primers for quantitative PCR of human NOP56 cDNA are described in Supplemental Table 3 . Immunoblotting was performed using an anti-human NOP56 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). We found no decrease in NOP56 RNA expression or protein levels in LCLs from these patients ( Figure 5A ). To investigate abnormal splicing variants of NOP56, we performed RT-PCR using the primers covering the region from the 5' UTR to exon 4 around the repeat expansion (Supplemental Table 3 ); however, no splicing variant was observed in LCLs from the cases (Figure 5B ). Furthermore, immunocytochemistry for NOP56 and coilin, a marker of the Cajal body, where NOP56 functions 16 , was carried out. NOP56 and coilin distributions were not altered in LCLs of the SCA patients ( Figure 5C ), suggesting that qualitative or quantitative changes in the Cajal body did not occur. These results indicated that haploinsufficiency could not explain the observed phenotype.
We performed fluorescent in situ hybridization to detect RNA foci containing the repeat transcripts in LCLs from patients, as previously described 17; 18 . Lymphoblastoid cells from two SCA patients (Ped2_II-2 and Ped5_I-1) and two control subjects were
analyzed. An average of 2.1 ± 0.5 RNA foci/cell were detected in 57.0% of LCLs (n = 100) from the SCA subjects using a nuclear probe targeting the GGCCUG repeat, whereas no RNA foci were observed in control LCLs (n = 100) ( Figure 6A) . In contrast, a probe for the CGCCUG repeat, another repeat sequence in intron 1 of NOP56, detected no RNA foci in either SCA or control LCLs (n = 100 each) ( Figure 6A) indicating that the GGCCUG repeat was specifically expanded in the SCA subjects. The specificity of the RNA foci was confirmed by sensitivity to RNase A treatment and resistance to DNase treatment ( Figure 6A) .
Several reports have suggested that RNA foci play a role in the etiology of SCA through sequestration of specific RNA-binding proteins [5] [6] [7] . In silico searches (ESEfinder 3.0) predicted an RNA-binding protein, SRSF2 [MIM 600813], as a strong candidate for binding the GGCCUG repeat. Double-staining with the probe for the GGCCUG repeat and an anti-SRSF2 antibody (Sigma-Aldrich Inc., Tokyo, Japan) was performed.
The results showed co-localization of RNA foci with SRSF2, while NOP56 and coilin were not co-localized with the RNA foci (Figure 6B ), suggesting a specific interaction of endogenous SRSF2 with the RNA foci in vivo.
To further confirm the interaction, gel-shift assays were carried out to investigate the binding activity of SRSF2 with (GGCCUG) n . Synthetic RNA oligonucleotides (200 pmol), (GGCCUG) 4 or (CUG) 6 , which is the latter part of the hexanucleotide, as well as the repeat RNA involved in myotonic dystrophy type 1 (DM1) [MIM 160900] 18 and SCA8 [MIM 608768] 5 ,were denatured and immediately mixed with different amounts (0, 0.2, or 0.6 μg) of recombinant full-length human SRSF2 protein (Abcam, Cambridge, UK). The mixtures were incubated and the protein-bound probes were separated from the free forms by electrophoresis on 5-20% native polyacrylamide gels. The separated RNA probes were detected with SYBR Gold staining (Invitrogen, Carlsbad, CA, USA).
We found a strong association of (GGCCUG) 4 with SRSF2 in vitro in comparison to (CUG) 6 (Figure 6C) . Collectively, we concluded that (GGCCUG)n interacts with SRSF2.
It is notable that MIR1292 is located just 19 bp 3' of the GGCCTG repeat probes for miRNA (Invitrogen, Carlsbad, CA, USA) revealed that the levels of both mature and precursor MIR1292 were significantly decreased in SCA LCLs (Figure 6D) , indicating that the GGCCTG repeat expansion decreased the transcription of MIR1292.
A decrease in MIR1292 expression may upregulate glutamate receptors in particular cell types, e.g. GRIK3 in stellate cells in the cerebellum 23 , leading to ataxia because of perturbation of signal transduction to the Purkinje cells. In addition, it has been suggested, based on ALS mouse models 24; 25 , that excitotoxicity mediated by a type of glutamate receptor, the NMDA receptor including GRIN2B, is involved in loss of spinal neurons. A very slowly progressing and mild form of the motor neuron disease, i.e., mostly limited to fasciculation of tongue, limbs and trunk, may also be compatible with such a functional dysregulation rather than degeneration
In the present study, we have conducted genetic analysis to find a genetic cause for the unique SCA with motor neuron disease. With extensive sequencing the 1.8 MB linked region, we found a large hexanucleotide repeat expansions in NOP56, which were completely segregated with SCA in five pedigrees and was found in four unrelated cases with the similar phenotype. The expansion was neither found in 300 controls or other neurodegenerative diseases. We further proved that repeat expansions of NOP56 induce RNA foci and sequester SRSF2. Taken together, we thus concluded that hexanucleotide repeat expansions are considered to cause SCA by a toxic RNA gain-of-function mechanism and name this unique SCA as SCA36. Haplotype analysis indicates that hexanucleotide expansions are derived from a common ancestor. The prevalence of the SCA36 was estimate 3.6% in the SCA cohort in Chugoku district, suggesting that prevalence of SCA36 may be geographically limited to the western part 12 of Japan and is rare even in Japanese SCAs. Moreover, SCA36 is not merely a non-triplet repeat expansion disorder after SCA10, DM2, and SCA31, but is now proven to be a human disease caused by a large hexanucleotide repeat expansion. In addition, no or only weak anticipation has been reported for non-coding repeat expansion in SCA, while clear anticipation has been reported for most polyglutamine expansions in SCA 2 . As such, absence of anticipation in SCA36 is in accord with previous studies on SCAs with noncoding repeat expansions.
Expansion of tandem nucleotide repeats in different regions
The common hallmark in these noncoding repeat expansion disorders is transcribed repeat nuclear accumulations with respective repeat RNA-binding proteins, which are considered to primarily trigger and develop the disease at the RNA level. However, multiple different mechanisms are likely to be involved in each disorder. There are at least two possibilities to explain motor neuron involvement of SCA 36: gene and tissue specific splicing specificity of SRSF2 and involvement of microRNA. In SCA36, there is the possibility that the adverse effect of the expansion mutation is mediated by 13 downregulation of microRNA expression. The biochemical implication of microRNA involvement cannot be evaluated in this study, because availability of tissue samples from affected cases was limited to LCLs. Given definitive downregulation of microRNA 1291 in LCLs, we should await further study to substantiate its involvement in affected tissues. Elucidating which mechanism(s) play a critical role in the pathogenesis will be required to determine whether cerebellar degeneration and motor neuron disease occur with a similar scenario.
In conclusion, expansion of the intronic GGCCTG hexanucleotide repeat in Table 3 ), and labeled with 32 P-dCTP. A scatter plot shows no negative correlation between GGCCTG repeat number and onset age (n=17, r=0.42, p=0.09). TCCAGGCCATCTATAGGGCA  exon 4  TCCCCTACCTTTATGCACCA  AACATACTCCCACGCAGAAGA  STK35  exon 1  CGGATCACGGGAATTTCG  ATTGGCTGAAAAGTTCGGCT  exon 2  TGGCTTCCGTCTTAAAGGG  CAGGAAAGGAGGGTGTGTCA  exon 3  GTCCCCTTGGAGCAGTTGTTT  AATCACTTGAACTCGGGAGGT  exon 5  TCTCTTTAGAGCTCTGCCCCA  TTGCCCACATTGAATTTCTT  TGM3  exon 1  TTATTATCTGCCCCCTTCTCC  CTCTGGCTAGCACCCTAAAAT  exon 3  AACAGGATGCACAGAGGTTCA  TCCCTCTTGATTTGAGGATGG  exon 4  TGGCCTGTATGTTTGTTCCA  TTGGGGCTTGGAGAGATAGAA  exon 5  TCAGGGGAGGGCTAAAGGT  AGGTGGCCAATGAAAGTCTT  exon 6  TTCCTGTGGTTCTTGCCAGT  TGTAAAGAGTGTGCGTGCCTA  exon 7,8  TTCAATCATGGCCTTTGGCT  AATCAGCATTGCCAGCAGTT  exon 9  TGTTGTCATGCTGCACTGTTG  TTGTTTTAATCCCATCATGCA  exon 10  GGTTGCAGTGGTCCTGGAA  GCAATCCTATCATTCAGGCA  exon 11  TGAAAGTCGAATGCCTGCTA  TCCAAAGCATTAATACATGGC  exon 12  AGATCCTCCCACCAGCTCA  AAAACTCTCCTTTGCCCTCTG  exon 13  TCTCCCCTTCTTCATCCTCA  CCAAACCAAATGCAAAAGCAG  exon 14  CTCCATCAGAACAGGACAGGA  CACTCCCTTTGGACATTGAA  TGM6  exon 1  TGATTTTGTGTCTCGTGGGTG  AGTTCATGTGTTCATGGTGGA  exons 2,3  ATGAACAAATGACTGGCCGA  TAAGTTCTTGCCCAGCTCTTG  exon 4  AAGCCCCCTCTTGACCTCT  CCTGGCCCAGTGAATAGTAGA  exon 5  TTGAGGAAGGGTTTCCAAGAC  CAGCGAATTAAAACAAGGGG TGGTTTAGGTGATTTCTGCCC  GCTTTCCTTGGTAACTGTGGA  exon 12  TGCCTGGCTACTTTTTGTGGA  ATGCCACCACATCTGGCTAAT  exon 15  TGAGGAAGCATGCATATCAGG  CAATGCTGAGCATTCAATTCC  exon 16  TGTTGAGGGGGATTGGTCT  CTTCACTCATGCTAACCCAAA  exon 17  CCAGACCACTGTCCAAAGTTT  AGGGGAAAAACAACACAAAGA  exon 20-1  CACCTCAATAGCCCTGGCAT  TGGGCTTGGACAGATGGAA  exon 20-2  TTCCAGTGTGCCAAGGGTAA  TGGAGGCTAAACGGGGTTCTA  exon 21  TCTTACAGGCTTGGTCCATGA  GGTGAGGCAAATCTCACTTCA  exon 24  TAAGGAGCTTGTGGCTGTTTC  ACCTTGGCCTTCCAAAGTTCT  exon 25  TGGCATCTTTATACAAGCGTG  ACATGGGAAACCATAGGGAA  exon 27  CCTGGCCTGGATTTCTTATT  CAAGGACAGAGGGCCTTATTA  exon 28  CCTGGCACATACATGGTAGAA  TCTAGGCACACACCTGAGGTT  exon 29  AAGAGGTCAAAGGGCCTTCT  TTTCCACAGTGCTTGGTCAT  exon 30  TTTTAGTTCTGACCCTGCCA  TAATCTTGGAGGACTGCCCTA  exon 31  TTCTAGCTGGAGGTCAGGATT  TTGGGGCTAGGGTTACAGATT  exon 32  TGCATTTCAAGTCCCACTTCA  AGTGATTCCAACGTGCAGGAT  exons 33,34  CCAGCTGAACATATGGGAACA  AGTGGGTGGGTGAGTATCAAT  exon 35  CAGAAAGCAACCAGCTTGTCA  TTGGGAGAAGCTAATGACTGC  exons 36,37  ACGAAGCGTATCAGCGTAAGA  TAGCATCCAATCCTGTCTTGG  exon 38  TGAGTCCCTCCACAGCACAT  TATGCTCCCATTGCTGCCAT  exon 39  CAGAGCTCAGGTGAAAGTTCA  TTTCTCGGCTGAGGATTTCA  GNRH2  exon 2, 3  GCAGAGAGGGAAGGGCATAA  TGAGAAATGGCTGGGGGT  exon 4  TAGCTGGATCCTCAGGCTTCT  GGGGCCATCCCTTAGTTACT  MRPS26  exon 1  TTCGGTTCCAGAGGCCACA  TTCCTCTGCACCTCGGACA TTGGAGTCGAGAGAAAGGGGTA  exon 2  CCTTGCCAGTCAGACTGAGA  AACAAATGCCAGGTCCCAA  exons 3,4  AGTGACATTTGCAGGTGGGT  AGGGACCAAATAAACCAGGA  exons 5,6  TTGGGGGAATGGAGAAATG  GGGTTGGAGGGAGAGAAACT  exons 7,8  TACAGTGTTTTTCCAGCCACC  TCCTCCTTGTAACTGCATCCA  exon 9  TGATTCGACTCTCCTAGCAGG  TTATCTAGGTCTTGGGGGCA  ITPA  exon 1  AGAGAAGAGCGAAAGCAGGG  TTCTTGCGCCCCAGCTTTT  exon 2, 3  GTAAGCTTTAGGAGATGGGCA  CGGTCCTAGAAAGCTCAACAA  exon 4  CCAAAGTTAAGAGATTGGCCG  AAAGAAAGGCATGCTTCTCC  exon 5  TGCTGGGATTATAGGCGGGA  TACAGGGTACGAGCTGCAGGT  exon 6  CCGCTACCCCAATTGAGA  TGAAAAGCTGGAAAGGCTGA  exon 7  AGCAAACATTTGCAGGTGCT  AGATTCCTAGTGTCCACCCCA  exon 8  ACTCCCCTTTCCTTGGGGT  TCCACTTGCCAGAGTTTCTCA  SLC4A11 exon 1  AGTCGAACGTTTTCCCAGAAG  CAGAGCCCTAATGAAACCA  exon 2,3  TTTTGGACCAACGGCTCTG  AGATAGGCGAGCAAAGCCA  exon 4,5  TTCCTCGCCTATGGGATG  TCCTGGAGGCATGGGAAGA  exon 6,7  TGATGGCTTCCCTGAGAAT  TCTTCTCCCAAGTTGGTTGG  exon 8  TTTTCCCTCCCTAGCAGAGGT  CAACATGTTTCTGACACACCCA  exon 9,10,11  AAAACCTGCTGCCAGTTCATG  AATGGCTGCCCAGAGAAGA  exon 12  ATCGCTTTCGGGTCTCTCAA  TTGGGGCAGCAATATGGT  exon 13  ACCATATTGCTGCCCCAA  TTGATCACGGGCACACACT  exon 14,15,16  TTGATCACGGGCACACACT  TTCACCAGCCTGCAGCAGA  exon 17,18  TTGGTGAATGCACCGGAGAA  ACCCTCCGGATGTAGTGTGT  exon 19,20  CTCTATGGCCTCTTCCTCTACAT  AGTCACCCACACACCTACACCT  C20orf194 exon 2  TTAAGAAGTGGGGTCCCTGT  TGAGCCGTTCAGCAAAGAA  exon 3  ATCCCCAGCAAAGTCATTCCT  ACAAATTTCGGGGGAACAAG  exon 4  GTTTCTGGCACAAAACTGGT  ACTGGGGCTTTGGACTATTT  exon 5  TTTGGTTTACAAGGCACAGTG  TCCTTTTGTCTCCACAGGCATA  exon 6  CTTTGGAAACACCTCCTTGGGT  TTGCACAGAAAAGTCCCCAT  exon 7  TTTTGCTAGGTGAGGCCCT  TAACTTGCTCCATGCCCTTGT  exon 9  TCTGTATGTGCATGTGTGTATGT  TGACCGAAGCAAACTAAAATATCC  exon 10  GAGATTCATCCATAGGAGTAGCA  GGGGGGAACTACTTTATGGTAT  exon 11  CACTCTCCTGAAGCATGTGTGTA  GCAGAGAAACAGACACATTTACAG  exon 12  CTAGCTTGAGTTTAGTTATGTCCC  GGGTTAAATCAACACACTAACTGG  exon 13  CCATCCTACATGACAGAGTAAGAC  ATCCAGAAGTAATCAGAGAGGGAG  exon 14  TGGGCGACAAAGCTAAACTG  TTATGTTGCCCAGGCTGGT  exon 15  GCCCAGGCATGTGACTTTT  TGGTGTCAAAGAGGCCCAA  exon 17  TCATGCCTACCAAGTAGTCACAT  TTTGGCTTCTAAGTGAAGGCTG  exon 18,19  AAGGATGACACACACCTCACTGT  TGGGATAGGACTGAGAGAAGATCA  exon 20  AAAGTCACCTCCCAGTTCAAAGA  AGTGCAGTGCTGTGATCATCA  exon 21  AGCTCCTGAGAAGGGCATTT  AACAGCTAGTTCAGGACCTGACAT  exon 22  ACATGGACATGGTGGAAGGA  AGGGGAGGAATGCAAATAGGAA  exon 23  ATACATTGGGCATATCTGAGCCT  TCATCTACAAAGTGGGTGGGT  exon 24  CACAGGGCTCAGCATACAAATC  TGTGCTGGTTCCTGACATACTG  exon 25  AGCACATCTATACTGAACCACAG  ATTAGAAGCAGTCACCCCACA  exon 26  TCAGGCCTCTATTTTTGAAGCA  GCAAGTTGGCAGCATTGAAA  exon 27,28  GTGTTTTGGAAGAGTTGACTCTG  AAGGAAGTGGAGAGTCCTGTAA  exon 29  TGGCCTAAGGTCACAGAGTTAGT  TACAGGAAGTGCTCAGAAGAGCAT  exon 30  CCAAGATGGCTTTCTCCTGAATG  CTGCTCATGCATGTAGAGTCTGTT  exon 31  AGATTGCGGGCTCTTCCTTTT  TCCAAAGGGGTCTATTGAGGA  exon 32  CATGGCTATCCTTAGTGCTCAGT  GCTCTTGGAAGAAATGTGCCTA  exon 33  TATTGGGGTGTAAGGGTTGTCT  TGGCTCAAAAACTGACTTCTCC  exon 34  ATTACCTGGGTATGATGGCACA  TTGCTGCCTACAGGATGATT  exon 35,36  GACGGGGTTTCACCTTGTTAG  TTTCTGAGAGTCTGAGCAGCAT  exon 37  ACCTACTCCATCCTTTCTAAGCTG  TCTCTCAAAGTGTCCCTGCAA  exon 38  TTATATCCAGGCCATAGCGCA  AATTCTGTACGCAGCTTCCCT  exon 39  AGGCAGGGCTTGAGGTTT  TTTGCCCCTGTGCATTCCT  exon 40 ACAAAGAGTCCATCAGGTTCCCT ACAACATGCACTCAAGCCA
Supplemental

